By Andrew Boyce, Lewis Crofts and Nicholas Hirst ( October 30, 2025, 15:10 GMT | Insight) -- Pfizer has heavily criticized Novo Nordisk’s bid for Metsera, calling it an attempt by a dominant company to illegally suppress competition by acquiring an “emerging challenger.” Denmark’s Novo Nordisk has structured the deal “in a way to circumvent antitrust laws,” Pfizer said, adding that it “carries substantial regulatory and executional risk.”Pfizer has lashed out at Novo Nordisk’s bid for Metsera, calling it an attempt by a dominant company to illegally “suppress competition” by acquiring an “emerging challenger.”...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.